Absence of tumor-infiltrating lymphocyte is a reproducible predictive factor for sentinel lymph node metastasis: A multicenter database study by the Brazilian melanoma group

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Duprat, João Pedreira ^a   Brechtbülh, Eduard René ^a   De Sá, Bianca Costa ^a   Enokihara, Mauro ^b   Fregnani, Jose Humberto ^c   Landman, Gilles ^b   Maia, Marcus ^d   Riccardi, Felice ^e   Belfort, Francisco Alberto ^f   Wainstein, Alberto ^g   Moredo, Luciana F ^a   Steck, Higino ^h   Brandão, Miguel ⁱ   Moreno, Marcelo ^j   Miranda, Eduardo ^k   De Oliveira Santos, Ivan Dunshee ^b  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Barretos Cancer Hospital   (Brazil)

^d Santa Casa de Misericordia de Goiania   (Brazil)

^e HOSPITAL SANTA RITA   (Brazil)

^f HOSPITAL SÍRIO LIBANÊS   (Brazil)

^g Faculty of Medical Sciences of Minas Gerais   (Brazil)

^h Campinas   (Brazil)

ⁱ Multidisciplinary Oncology Care Clinic   (Brazil)

^j Universidade Comunitaria Regional de Chapeco   (Brazil)

^k FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TUMOR ASSOCIATED LEUKOCYTE; BRAZIL; CELL COUNT; CYTOLOGY; FACTUAL DATABASE; IMMUNOLOGY; LYMPH NODE METASTASIS; META ANALYSIS; PATHOLOGY; PROGNOSIS;

BRAZIL; CELL COUNT; DATABASES, FACTUAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84959386775     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148160     Document Type: Article

References (37)

1. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol. 2012; 19:3313-24. doi:10.1245/s10434-012-2475-3 PMID: 22766987.
2. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges.2008; 6(Suppl 1):S9-S14. doi:10.1111/j.1610-0387.2008.06711.x PMID: 18801142.
3. Kaur C, Thomas RJ, Desai N, Green MA, Lovell D, Powell BW et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol.2008; 61:297-300. PMID: 17675538.
4. Murali R, Haydu LE, Quinn MJ, Saw RPM, Shannon K, Spillane AJ et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg.2012; 255:128-133. doi:10.1097/SLA.0b013e3182306c72PMID: 21975320.
5. Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, et al. Sentinel Node Biopsy is Indicated for Thin Melanomas -0.76 mm. Ann Surg Oncol.2012; 19:3335-42. doi:10.1245/s10434-012-2469-1 PMID: 22766986.
6. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw.2013; 11:395-407. PMID: 23584343.
7. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF; MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med.2014; 370:599- 609. doi:10.1056/NEJMoa1310460 PMID: 24521106.
8. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenbom T et al. Malignant melanoma S3- guideline"diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges.2013; 11(Suppl 6):1- 116. doi:10.1111/ddg.12113-suppl PMID: 24028775.
9. Australian Cancer Network and N.Z.G. Group. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. [Approved 31 October 2008]. Available: http://www.nhmrc.gov.au/-files-nhmrc/publications/attachments/cp111.pdf.
10. Pena SDJ, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy F de S et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One.2011; 6:e17063. doi:10.1371/journal.pone.0017063 PMID: 21359226.
11. Bakos L, Wagner M, Bakos RM, Leite CS, Sperhacke CL, Dzekaniak KS et al. Sunburn, sunscreens, and phenotypes: some risk factors for cutaneous melanoma in southern Brazil. Int J Dermatol.2002; 41:557-62. PMID: 12358823.
12. Kunte C, Geimer T, Baumert J, Konz B, Volkenandt M, Flaig M et al. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: An analysis of 1049 patients with cutaneous melanoma. Melanoma Res.2010; 20:330-7. doi:10.1097/CMR.0b013e32833ba9ffPMID: 20526218.
13. White RL Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC et al. Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database. Ann Surg Oncol.2011; 18:3593-3600. doi:10.1245/s10434-011-1826-9 PMID: 21647761.
14. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol.2012; 30:2678-83. doi:10.1200/JCO.2011.37.8539 PMID: 22711850.
15. Roach BA, Burton AL, Mays MP, Ginter BA, Martin RCG, et al. Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg.2010; 200:759-63. doi:10.1016/j.amjsurg.2010.07.037 PMID: 21146017.
16. Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver SB et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol.2013; 31:4252-9. doi:10.1200/JCO.2013.51.3002 PMID: 24127443.
17. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol.2007; 25:869-75. PMID: 17327608.
18. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J.2012; 18:160-75. doi:10.1097/PPO.0b013e31824d4465 PMID: 22453018.
19. Neves R.I, Belfort F, Brandão M, Castanheira D, Jorge D, Parro F et al. Relatório Final do consenso nacional sobre linfonodo sentinela (LNS) do Grupo Brasileiro de Melanoma. Acta Oncol Bras.2003; 23:499.
20. Landman G, Muller H, Fillus Neto J, Macieira JM, Marques M, Costa MB et al. Consenso para o laudo anatomopatológico do melanoma cutâneo: Grupo Multicêntrico e Multidisciplinar Brasileiro para Estudo do Melanoma (GBM). Acta Oncol Bras.2003; 23:7.
21. Duprat JP, Silva DCP, Coimbra FJF, Lima IAM, Lima ENP, Almeida OM et al. Sentinel lymph node biopsy in cutaneous melanoma: Analysis of 240 consecutive cases. Plast Reconstr Surg.2005; 15:1944-51.
22. Thomas J.M., Where is the evidence base for benefits of sentinel node biopsy in melanoma? BMJ.2013; 346:f675. doi:10.1136/bmj.f675 PMID: 23390236.
23. Pasquali S, Haydu LE, Scolyer RA, Winstanley JB, Spillane AJ, Quinn MJ et al. The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. Ann Surg.2013; 258:152-7. doi:10.1097/SLA.0b013e31828421e1 PMID: 23426339.
24. Kretschmer L, Thoms K-M, Peeters S, Haenssle H, Bertsch H-P. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res.2008; 18:16-21. doi:10.1097/CMR.0b013e3282f2017d PMID: 18227703.
25. de Vries M, Hoekstra HJ, Hoekstra-Weebers JEHM. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol.2009; 16:2840-7. doi:10.1245/s10434-009-0602-6 PMID: 19639366.
26. Day CL Jr, Sober AJ, Kopf AW, Lew RA, Mihm MC Jr, Hennessey P et al. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg.1981; 193:436-40. PMID: 7212806.
27. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest.1996; 74:43-7. PMID: 8569196.
28. Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol.2014; 1102:287-324. doi:10.1007/978-1-62703-727-3-16 PMID: 24258985.
29. Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer.2006; 107:2436-45. PMID: 17058288.
30. Balch CM, Gershenwald JE, Soong S- J, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol.2009; 27:6199-6206. doi:10.1200/JCO.2009.23.4799PMID: 19917835.
31. White RL Jr, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC et al. Sentinel Lymph Node Working Group. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol.2011; 18:3593-600. doi:10.1245/s10434-011-1826-9 PMID: 21647761.
32. Burton AL, Gilbert J, Farmer RW, Stromberg AJ, Hagendoorn L, Ross MI et al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg.2011; 77:1009-13. PMID: 21944515.
33. Olah J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol.2003; 149:662-3. PMID: 14511013.
34. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol.2003; 25:371-6. PMID: 14501285.
35. Murali R, Haydu LE, Long G V, Quinn MJ, Saw RPM, Shannon K et al. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Ann Surg Oncol.2012; 19:1782-9. doi:10.1245/s10434-012-2265-y PMID: 22350600.
36. Requena C, Botella-Estrada R, Traves V, Nagore E, Almenar S, Guillén C. Problems in defining melanoma regression and prognostic implication. Actas Dermosifiliogr.2009; 00:759-66. PMID: 19889297.
37. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol.2008; 15:316-22. PMID: 18004626.